ND108E is First-in-class for Alzheimer’s Disease
↓ 16% cortex amyloid plaque
↑ 84% cognitive performance recovered
> 90% spine plasticity and synaptic function restored in animal models.

Under HylNeuro™ platform, ND108E employs hyaluronic acid (HA) as a drug carrier across the blood-brain barrier (BBB).
ND108E is a CNS-targeted HA conjugate designed to restore cognition in post-menopausal Alzheimer's patients.
Through precise targeting to cortex and hippocampal neurons, ND108E can avoid systemic off-target toxicity
• Preclinical Data: Reversal of learning and memory deficits in behavioral models
• Mechanism: Amyloid plaque reduction; increased spine density and restored ChAT activity
• Status: IND-enabling studies in progress